Opaleye Management Inc.
BOSTON, MA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$887.7M2026 Q3
Positions58
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.62.6%
What Changed This Quarter?
Top Holdings
ETON
Eton Pharmaceuticals
14.2%
IRON
Disc Medicine
8.1%
HROW
Harrow
7.3%
LQDA
Liquidia
7.2%
URGN
UroGen Pharma
6.6%
SLGL
Sol-Gel Technologies
4.6%
MGTX
MeiraGTx
4.5%
TGTX
TG Therapeutics
3.5%
New / Increased
10 new · 17 increased
SMMTNEW
Summit Therapeutics
2.0%
HRMYNEW
Harmony Biosciences Hldgs
1.0%
GRCENEW
Grace Therapeutics
0.7%
SNDXNEW
Syndax Pharmaceuticals
0.7%
Gossamer BioNEW
Gossamer Bio
0.6%
IRON
Disc Medicine
8.1%
+28.1%
BHVN
Biohaven
1.8%
+1427.3%
VSTM
Verastem
2.5%
+53.0%
Reduced / Exited
19 reduced · 10 sold out
ETON
Eton Pharmaceuticals
14.2%
-14.7%
MBX
MBX Biosciences
0.1%
-92.3%
EWTX
Edgewise Therapeutics
0.8%
-65.0%
LQDA
Liquidia
7.2%
-13.8%
RZLT
Rezolute
1.9%
-35.1%
Apogee Therap…EXIT
Apogee Therapeutics
4.7%
XOMAGBPEXIT
Xoma Royalty
1.3%
NTLAEXIT
Intellia Therapeutics
0.4%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.